|
Forecast
Period
|
2026-2030
|
|
Market
Size (2024)
|
USD
5.10 Billion
|
|
Market
Size (2030)
|
USD
7.87 Billion
|
|
CAGR
(2025-2030)
|
7.45%
|
|
Fastest
Growing Segment
|
Humira
|
|
Largest
Market
|
North
America
|
Market Overview
Global Ankylosing Spondylitis Therapeutics Market was valued at USD 5.10 Billion in 2024 and is anticipated to project impressive
growth in the forecast period with a CAGR of 7.45% through 2030. Ankylosing
Spondylitis Therapeutics (AS) is a chronic inflammatory autoimmune disease that
primarily affects the spine, leading to pain, stiffness, and decreased
mobility. This condition is part of a group of disorders known as
spondyloarthritis, which can also affect other joints and organs. The global Ankylosing
Spondylitis Therapeutics market has been witnessing significant developments in
recent years, driven by advances in research, innovative therapies, and
increasing awareness. Ankylosing Spondylitis
Therapeutics is characterized by inflammation of the sacroiliac joints, which
connect the base of the spine (sacrum) to the pelvis. Over time, this
inflammation can lead to the fusion of spinal vertebrae, causing a loss of
flexibility and posture changes. The disease typically begins in early
adulthood, with symptoms such as lower back pain and morning stiffness. Early
diagnosis and effective management are crucial for improving patients' quality
of life. AS is a global concern,
affecting millions of people worldwide. The exact prevalence varies among
different regions, with higher rates in certain populations. While the cause of
AS remains unclear, genetic factors, particularly the HLA-B27 gene, play a
significant role in its development. The global AS market has
witnessed substantial growth in recent years due to several factors. Improved awareness among healthcare professionals and patients has led
to earlier diagnosis and treatment, enhancing the overall market growth. The
advent of biologic drugs, such as tumor necrosis factor (TNF) inhibitors, has
revolutionized AS treatment. These drugs target specific components of the
immune system, providing more effective symptom management. Pharmaceutical companies are investing heavily in research and
development to identify novel therapeutic targets and drugs. This has resulted
in a pipeline of potential treatments in various stages of development. AS is more commonly diagnosed in younger adults, and as the global
population ages, the number of AS patients is expected to rise, driving market
expansion.
The treatment of AS
primarily focuses on symptom management, pain relief, and slowing down disease
progression. Nonsteroidal anti-inflammatory drugs (NSAIDs) are commonly
prescribed to alleviate pain and inflammation. Additionally, physical therapy
and exercise play a crucial role in maintaining joint mobility. Biologic
therapies, such as TNF inhibitors (e.g., adalimumab, etanercept), have
revolutionized AS treatment. These drugs can effectively reduce inflammation
and improve patients' quality of life. However, they come with a significant cost
and potential side effects, including increased susceptibility to infections.
The global AS market is
poised for further growth and innovation. Several key trends and developments
are shaping its future. Ongoing research is
uncovering new treatment targets and potential therapeutic agents beyond TNF
inhibitors. This includes drugs targeting interleukins and other immune system
components. Advancements in genetics
and biomarker research are paving the way for personalized treatment
approaches, ensuring that patients receive the most effective therapies
tailored to their specific needs. As patents for some biologic drugs expire, the introduction of
biosimilars may increase affordability and access to effective treatments. The integration of telemedicine is making healthcare more accessible for
AS patients, allowing remote monitoring and consultations, particularly
relevant for individuals with limited mobility.
Key Market Drivers
Rising Prevalence of Ankylosing Spondylitis
The increasing global prevalence of ankylosing spondylitis is one of the most significant factors fueling the growth of the ankylosing spondylitis therapeutics market. Ankylosing spondylitis (AS) is a chronic, immune-mediated inflammatory arthritis that affects a relatively small but clinically significant segment of the global population, with prevalence rates ranging from approximately 0.1% to 1.4%. The condition disproportionately affects males and commonly manifests during the peak of working-age productivity, typically in the mid-20s. This rise is not only expanding the patient population but also intensifying the demand for effective and long-term treatment options, thereby opening substantial growth opportunities for pharmaceutical companies and healthcare providers. As more individuals worldwide are diagnosed with AS a chronic, inflammatory disease that primarily affects the spine and sacroiliac joints the size of the target population continues to grow. The increasing number of patients directly translates into higher demand for diagnosis, disease management, and therapeutics. Traditionally, AS has been underdiagnosed or diagnosed late due to its gradual onset and nonspecific symptoms. However, with rising awareness and advancements in imaging technology and diagnostic criteria, more cases are being identified in earlier stages. Early diagnosis allows for timely intervention, increasing the likelihood of patients being placed on long-term treatment plans, thereby boosting demand for therapeutic products.
As the number of individuals suffering from AS rises, so does the overall healthcare burden associated with managing the disease. AS is a progressive condition that can lead to reduced mobility, decreased quality of life, and long-term disability. The chronic nature of the disease requires continuous therapeutic support, including anti-inflammatory drugs, biologics, and physical therapy. This long-term treatment requirement leads to recurring revenue streams for companies offering AS therapeutics. In 2021, global health expenditures surged to USD9.8 trillion, representing 10.3% of the world’s GDP. Notably, the United States accounted for over USD4 trillion of that total more than 40% yet continues to face stagnating life expectancy outcomes. This disconnects between escalating healthcare investment and minimal gains in population health highlights systemic inefficiencies and underscores the urgent need for value-driven, outcome-based healthcare models. The rising prevalence has led to greater focus from medical professionals, patient advocacy groups, and healthcare systems. Campaigns focused on early detection and education are helping reduce the stigma and misconceptions associated with AS. As patients become more proactive about seeking treatment, the demand for reliable and effective therapies increases benefiting both established and emerging players in the market.
Digital Health Integration and Personalized Medicine
The convergence of digital health technologies and personalized medicine is reshaping the ankylosing spondylitis therapeutics landscape, introducing a new era of data-driven, patient-centric care. These advancements are not only improving clinical outcomes but also unlocking significant commercial opportunities for biopharma companies, digital health providers, and healthcare systems globally. Digital health tools such as wearable devices, mobile health apps, and AI-powered platforms are enhancing real-time monitoring of ankylosing spondylitis symptoms, such as pain intensity, mobility limitations, and fatigue. These tools enable clinicians to track disease progression and treatment responses more accurately and intervene proactively, which improves therapeutic adherence and long-term patient outcomes. This data-centric approach supports chronic disease management models and increases patient retention on prescribed therapies resulting in consistent demand for pharmaceutical products and value-added services. Digital therapeutics platforms, telemedicine, and automated reminders are helping patients remain consistent with their treatment regimens a critical factor in chronic inflammatory diseases like AS, where discontinuation rates can be high. Increased patient engagement leads to improved therapy persistence, reducing clinical setbacks and increasing drug utilization rates. This, in turn, contributes to higher revenue continuity for drug manufacturers and service providers.
Digital health technologies generate vast amounts of real-world data, which pharmaceutical companies are leveraging to support regulatory submissions, post-market surveillance, and payer negotiations. In the AS therapeutics market, real-world evidence helps demonstrate long-term efficacy, safety, and cost-effectiveness of both innovative biologics and biosimilars, accelerating market access and reimbursement approvals especially in value-conscious healthcare systems. Personalized medicine enabling targeted treatment approaches based on a patient’s genetic profile, biomarker expression, and immune response characteristics. In AS, this means moving beyond the traditional one-size-fits-all treatment model to more precise selection of therapies such as TNF inhibitors or IL-17 inhibitors, depending on individual disease drivers. As pharmacogenomics and molecular diagnostics advance, companies that integrate companion diagnostics with therapeutic offerings can differentiate their portfolios and command premium pricing.
Download Free Sample Report
Key Market Challenges
Limited Awareness and Early Diagnosis
One of the fundamental challenges in the AS market
is the lack of awareness among both healthcare professionals and the general
public. AS is often misdiagnosed or diagnosed late, delaying proper treatment
and potentially worsening the patient's condition. Raising awareness about the
disease, its symptoms, and the importance of early diagnosis is crucial to
improving patient outcomes.
Complex Diagnosis and Misdiagnosis
AS diagnosis can be challenging due to its variable
symptoms and the need for specialized tests, such as HLA-B27 genetic testing
and imaging studies like MRI or X-rays. Misdiagnosis or delayed diagnosis can
lead to inadequate treatment and prolonged suffering for patients. Ensuring
that healthcare providers have access to the necessary tools and knowledge for
accurate diagnosis is essential.
Limited Treatment Options
While there have been significant advancements in
AS treatments over the years, there remains a limited number of approved drugs
specifically targeting this condition. The market lacks diversity in treatment
options, which can result in patients not responding well to available
therapies. Expanding the treatment arsenal is essential to meet the unique
needs of individual patients.
Key Market Trends
Technological Advancements
The accurate and early diagnosis of AS is crucial
for effective management. Technological advancements have revolutionized the
way AS is diagnosed. Magnetic Resonance Imaging (MRI) and computed tomography
(CT) scans are now widely used to detect inflammation and structural damage in
the spine and sacroiliac joints. These imaging techniques offer high-resolution
images, allowing healthcare professionals to identify AS at its early stages
when treatment can be most effective. Additionally, the development of AI-driven
image analysis tools has improved the speed and accuracy of AS diagnosis.
Machine learning algorithms can analyze MRI and CT scans to identify subtle
changes that might be missed by human radiologists, ensuring earlier and more
accurate diagnoses.
In the past, AS was
primarily managed with non-steroidal anti-inflammatory drugs (NSAIDs) and
physical therapy. However, technological advancements in the field of
biotechnology have given rise to a new class of drugs known as biological
therapies. These medications target specific proteins in the immune system that
contribute to the inflammation seen in AS. Biological therapies, such as tumor
necrosis factor (TNF) inhibitors, have been a game-changer for AS patients.
These drugs have shown remarkable efficacy in reducing pain, inflammation, and
stiffness associated with the condition. Moreover, the development of
biosimilars, which are more affordable versions of biologics, has increased
accessibility to these life-changing treatments.
The COVID-19 pandemic accelerated
the adoption of telemedicine and remote monitoring technologies across various
medical specialties, including rheumatology. For AS patients, this has meant
easier access to healthcare professionals and improved disease management. Telemedicine
allows individuals with AS to consult with rheumatologists and other
specialists from the comfort of their homes, reducing the need for travel and
facilitating more frequent check-ups. Patients can discuss their symptoms,
medication adjustments, and treatment plans with their healthcare providers
through video calls and secure messaging platforms. Furthermore, wearable
devices and smartphone apps have enabled remote monitoring of AS symptoms.
These technologies can track physical activity, sleep patterns, and pain
levels, providing valuable data for both patients and healthcare providers to
better understand and manage the disease.
The internet and mobile
applications have made it easier for AS patients to access information,
educational resources, and support networks. Online platforms and mobile apps
provide a wealth of information about AS, including its symptoms, treatment
options, and lifestyle recommendations. Patients can also connect with others
who share their experiences, providing emotional support and practical advice. Additionally,
chatbots and virtual assistants powered by AI have been developed to answer
common questions and provide real-time assistance to AS patients. These tools
are available 24/7, offering immediate help when needed.
Segmental Insights
Drug Insights
Based on the drug, the Humira drug segment emerged
as the fastest growing segment in the global market for Ankylosing Spondylitis
Therapeutics Market in 2024. Humira has demonstrated efficacy in reducing the
symptoms and progression of ankylosing spondylitis in numerous clinical trials.
It is known to alleviate pain, stiffness, and inflammation in patients with AS.
Its proven track record made it a trusted and go-to option for both patients
and healthcare providers. Humira is a biologic drug, specifically a tumor
necrosis factor-alpha (TNF-alpha) inhibitor. AS is believed to involve an
overproduction of TNF-alpha, which plays a key role in inflammation. By
inhibiting TNF-alpha, Humira helps to control the inflammatory response and
manage the symptoms of AS. While Humira does come with potential side effects,
its safety profile has been well-documented through extensive clinical use.
This gave patients and healthcare providers confidence in its use. Humira is
administered via subcutaneous injections, which many patients find more
convenient than intravenous infusions. Its dosing schedule is typically every
two weeks or once a month, depending on the specific condition and the
patient's response. This ease of administration improves patient compliance. By
the time of my last update, Humira had been on the market for many years and
had gained extensive experience and data regarding its use in AS. This
long-term presence allowed it to become a trusted and widely prescribed treatment
option. The manufacturer, AbbVie, invested heavily in marketing and promotion
of Humira, making it a well-recognized brand in the AS treatment space. This
branding helped maintain its dominant position in the market. Due to its patent
protection and intellectual property rights, Humira had limited competition
from biosimilar products until those patents began to expire in certain
regions, leading to the eventual introduction of biosimilar versions of
adalimumab. Many insurance plans covered Humira, making it more accessible and
affordable for patients.
Download Free Sample Report
Regional Insights
North America emerged as the largest market in the
global Ankylosing Spondylitis Therapeutics market in 2024, holding the largest
market share in terms of value North America, particularly the United States
and Canada, boasts advanced healthcare infrastructures with a high
concentration of hospitals, clinics, and healthcare professionals. This allows
for easier access to diagnosis and treatment of AS, making it a significant
player in the global market. North America is home to many pharmaceutical and
biotechnology companies with substantial resources dedicated to research and
development of AS treatments. These companies often conduct clinical trials and
bring innovative therapies to market, contributing to the region's dominance. North
America has stringent regulatory agencies like the U.S. Food and Drug
Administration (FDA) and Health Canada, which ensure the safety and efficacy of
new AS treatments. These agencies often set the standards for the approval of
drugs and therapies, attracting investments and fostering innovation.
Recent Developments
- In September 2024, UCB, a global leader in immunology-focused biopharmaceutical innovation, announced that the U.S. Food and Drug Administration (FDA) has granted approval for BIMZELX® (bimekizumab-bkzx) for the treatment of adults with active psoriatic arthritis (PsA), non-radiographic axial spondyloarthritis (nr-axSpA) with objective signs of inflammation, and active ankylosing spondylitis (AS). BIMZELX is the first and only FDA-approved therapy that selectively targets both interleukin-17A (IL-17A) and interleukin-17F (IL-17F)—two key cytokines known to play a central role in the pathophysiology of these inflammatory conditions.
- In August 2023, Lynk Pharmaceuticals announced
favorable initial findings from a Phase II clinical study examining LNK01001 in
the treatment of ankylosing spondylitis (AS) among adult patients. This
extensive research, which included multiple centers, utilized a placebo-control
design with a double-blind, randomized methodology. The study was overseen by
Director Xiaofeng Zeng from the Rheumatology and Immunology department at the
Peking Union Medical College Hospital and the Chinese Academy of Medical
Sciences.
Key Market Players
- AbbVie, Inc.
- Amgen, Inc.
- Pfizer, Inc.
- Novartis AG
- Eli Lilly and Company
- UCB, Inc.
- Johnson & Johnson Services, Inc.
- Merck & Co., Inc
|
By Drug
|
By End Use
|
By Region
|
- Cosentyx
- Humira
- Simponi
- Remicade
- Enbrel
- Cimzia
|
|
- North
America
- Europe
- Asia Pacific
- South
America
- Middle East
& Africa
|
Report Scope:
In this report, the Global Ankylosing Spondylitis
Therapeutics Market has been segmented into the following categories, in
addition to the industry trends which have also been detailed below:
- Ankylosing Spondylitis Therapeutics Market, By Drug:
o Cosentyx
o Humira
o Simponi
o Remicade
o Enbrel
o Cimzia
- Ankylosing Spondylitis Therapeutics Market, By End Use:
o Hospitals
o Clinics
o Others
- Ankylosing Spondylitis Therapeutics Market, By
Region:
o North America
§ United States
§ Canada
§ Mexico
o Europe
§ France
§ United Kingdom
§ Italy
§ Germany
§ Spain
o Asia-Pacific
§ China
§ India
§ Japan
§ Australia
§ South Korea
o South America
§ Brazil
§ Argentina
§ Colombia
o Middle East & Africa
§ South Africa
§ Saudi Arabia
§ UAE
Competitive Landscape
Company Profiles: Detailed analysis of the major companies present in the Global Ankylosing
Spondylitis Therapeutics Market.
Available Customizations:
Global Ankylosing Spondylitis Therapeutics market
report with the given market data, TechSci Research offers customizations
according to a company's specific needs. The following customization options
are available for the report:
Company Information
- Detailed analysis and profiling of additional
market players (up to five).
Global Ankylosing Spondylitis Therapeutics Market
is an upcoming report to be released soon. If you wish an early delivery of
this report or want to confirm the date of release, please contact us at [email protected]